ArticleSurgery today2026
A prospective open label, multicenter phase 2 trial of full-dose gemcitabine and S-1 concurrent with radiation for locally advanced pancreatic ductal adenocarcinoma (BR + UR-LA) (CSGO-HBP-008).
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis prospective single-arm multicenter phase 2 trial investigated the efficacy and safety of chemoradiotherapy with gemcitabine (GEM) + S-1 (GSRT) in patients with locally advanced pancreatic ductal adenocarcinoma (PDAC) (BR + UR-LA).
methodsForty patients with locally advanced PDAC based on imaging findings were enrolled at three high-volume centers in Japan (April 2013-December 2018). The patient received full-dose GSRT concurrent with 50.4 Gy of radiation therapy. After chemoradiotherapy completion, the patients were reevaluated for surgical eligibility, and resection was performed if the tumors were considered resectable. In patients with unresectable tumors, chemotherapy was continued for over 6 months, and resection was performed if the tumors were considered resectable during the treatment course. The primary endpoint was the 1-year survival rate.
resultsThirty-nine patients received GSRT, and their 1-year survival rate, median overall survival time, and median progression-free survival time were 64.1%, 16.6 months, and 8.7 months, respectively. Twelve patients underwent radical resection, and their 1-year survival rate, median overall survival time, and median survival time were 91.7%, 44.3 months, and 11.6 months, respectively. The response and disease control rates were 25.6% and 79.5%, respectively. The GSRT completion rate was 95%, and adverse events were well tolerated.
conclusionsGSRT is a safe and effective treatment for patients with locally advanced PDAC.
trial registrationThis study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR: Registry No. UMIN 000011453).
Indexed as
Identifiers
42696140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.